The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon alpha-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.
Rice
G P
GP
London MS Clinic, Ontario, Canada.
Paszner
B
B
Oger
J
J
Lesaux
J
J
Paty
D
D
Ebers
G
G
D000937:Antigen-Antibody Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy*; D009500:Neutralization Tests; D013997:Time Factors
D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a